Technical Analysis for CTIC - Cell Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical CTIC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -5.65% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.65% | |
| 20 DMA Resistance | Bearish | -6.40% | |
| MACD Bearish Centerline Cross | Bearish | -6.40% | |
| Outside Day | Range Expansion | -6.40% | |
| 20 DMA Resistance | Bearish | -9.30% | |
| MACD Bearish Signal Line Cross | Bearish | -9.30% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Cancer Chemical Compounds Organic Compounds Cancer Treatments Acute Myeloid Leukemia Ovarian Cancer Antibody Drug Conjugates Seattle Genetics Ethers Head And Neck Cancer Pyrrolidines Treatment Of Acute Myeloid Leukemia Treatment Of Ovarian Cancer Camidanlumab Tesirine Myelofibrosis Triple Negative Breast Cancer Pacritinib Pixantrone Treatment Of Head And Neck Cancer
Cancer Chemical Compounds Organic Compounds Cancer Treatments Acute Myeloid Leukemia Ovarian Cancer Antibody Drug Conjugates Seattle Genetics Ethers Head And Neck Cancer Pyrrolidines Treatment Of Acute Myeloid Leukemia Treatment Of Ovarian Cancer Camidanlumab Tesirine Myelofibrosis Triple Negative Breast Cancer Pacritinib Pixantrone Treatment Of Head And Neck Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.93 |
| 52 Week Low | 0.6305 |
| Average Volume | 542,637 |
| 200-Day Moving Average | 0.94 |
| 50-Day Moving Average | 1.36 |
| 20-Day Moving Average | 1.28 |
| 10-Day Moving Average | 1.30 |
| Average True Range | 0.09 |
| ADX | 13.49 |
| +DI | 20.12 |
| -DI | 25.72 |
| Chandelier Exit (Long, 3 ATRs ) | 1.17 |
| Chandelier Exit (Short, 3 ATRs ) | 1.43 |
| Upper Bollinger Band | 1.42 |
| Lower Bollinger Band | 1.15 |
| Percent B (%b) | 0.08 |
| BandWidth | 20.86 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0147 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.31 | ||||
| Resistance 3 (R3) | 1.31 | 1.28 | 1.28 | ||
| Resistance 2 (R2) | 1.28 | 1.24 | 1.27 | 1.27 | |
| Resistance 1 (R1) | 1.22 | 1.22 | 1.21 | 1.22 | 1.27 |
| Pivot Point | 1.19 | 1.19 | 1.18 | 1.18 | 1.19 |
| Support 1 (S1) | 1.13 | 1.15 | 1.12 | 1.13 | 1.07 |
| Support 2 (S2) | 1.10 | 1.13 | 1.09 | 1.07 | |
| Support 3 (S3) | 1.04 | 1.10 | 1.06 | ||
| Support 4 (S4) | 1.04 |
